IL6 and metabolic dysfunction-associated steatohepatitis: Western blot analysis showed that cilostazol administration prevented the increase in IL-6 and F4/80 levels observed in NASH mice, indicating that the upregulated recruitment of monocyte-derived macrophages in NASH livers was resolved by cilostazol (Figure 2H).